echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Diagnostic Test > US FDA approves Tembexa: the first smallpox for all ages...

    US FDA approves Tembexa: the first smallpox for all ages...

    • Last Update: 2021-06-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chimerix recently announced that the US Food and Drug Administration (FDA) has approved Tembexa (brincidofovir) tablets and oral suspensions for the treatment of smallpox


    Tembexa is a lipid conjugate of nucleotide analogues, designed to simulate natural monoacyl phospholipids to achieve an effective intracellular concentration of antiviral active metabolite cidofovir diphosphate (cidofovir diphosphate)


    The FDA approved Tembexa, based on the efficacy data of two lethal orthopox virus animal models of human smallpox disease, namely the rabbitpox model (New Zealand white rabbits infected with rabbitpox virus) and the mousepox model (BALB/c infected with mousepox virus) Mice)


    The FDA's "Animal Rules" allow testing of experimental drugs in animal models to support the effectiveness of diseases that are not ethical or suitable for human research


    Smallpox is a highly contagious disease caused by the smallpox virus


    Smallpox virus is one of the most complicated viruses, with double-stranded DNA genome, brick-shaped virus particles, and a very small amount of virus can cause infection


    The molecular structure of brincidofovir (picture source: Wikipedia)

    The molecular structure of brincidofovir (picture source: Wikipedia)

    The active pharmaceutical ingredient of Tembexa is brincidofovir, which is a nucleotide analogue that has antiviral activity against all five DNA virus families that affect humans, including adenovirus and variola virus, the latter can cause smallpox


    brincidofovir uses Chimerix's lipid conjugation technology and compound library discovery with independent intellectual property rights


    Since 2011, Chimerix has been cooperating with the U.


    Original source:

    Original source:

    Chimerix Receives US Food and Drug Administration approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

    Chimerix Receives US Food and Drug Administration approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

    This article is from Bio Valley, for more information, please download the Bio Valley APP (http://

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.